PTJ
RAPP

Paul Tudor Jones’s Rapport Therapeutics RAPP Stock Holding History

Paul Tudor Jones’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,149
Closed -$331K – 4163
2025
Q3 		$331K Buy
+11,149
New +$199K ﹤0.01% 2919

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Paul Tudor Jones's RAPP Position: Q4 2025 in Review

Paul Tudor Jones sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 11,149 shares — an estimated $331K sold.

Paul Tudor Jones first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $331K in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Paul Tudor Jones reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 11,149 Rapport Therapeutics shares in Q4 2025, an estimated $331K.
  • Paul Tudor Jones first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
  • Paul Tudor Jones's Rapport Therapeutics position peaked at $331K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.